Vanda Pharmaceuticals (VNDA) Operating Leases (2019 - 2026)

Vanda Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Operating Leases fell 25.84% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 25.84% YoY), while the FY2025 annual figure was $3.0 million, down 75.8% from the prior year.
• Operating Leases came in at $3.3 million for Q1 2026 at Vanda Pharmaceuticals, up from $3.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $12.4 million in Q4 2024 to a low of $3.0 million in Q4 2025.
• A 5-year average of $7.0 million and a median of $7.5 million in 2023 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases soared 31.43% in 2024 and tumbled 75.8% in 2025, its largest moves.
• Vanda Pharmaceuticals' Operating Leases stood at $8.8 million in 2022, then climbed by 6.71% to $9.4 million in 2023, then jumped by 31.43% to $12.4 million in 2024, then sank by 75.8% to $3.0 million in 2025, then rose by 9.19% to $3.3 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $3.3 million, $3.0 million, and $3.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison